Antibiotic Pipeline Failure
Insufficient development and commercialization of new antibiotics is weakening the ability to treat drug-resistant bacterial infections. The supplied evidence indicates a substantial current health and economic burden from antimicrobial resistance and warns of much larger future losses if effective antibiotics remain unavailable.
Severity score
67.4
Critical · default weighting
Trajectory
Steady
What this is
Score breakdown
Each factor is a 0–100 relative severity index, not the raw figure or a specific time period. The actual counts and periods are listed under "Standardized Impact" on the right.
Loss of life
65Direct and attributable mortality, normalised across annual and cumulative tolls.
Lives negatively impacted
78People displaced, injured, food-insecure, exposed or otherwise materially harmed.
Financial cost
82Direct damage, lost output and health-system spend attributable to the event.
Environmental impact
20Emissions, habitat and biodiversity loss, contamination and irreversibility.
Trajectory
90Whether the situation is escalating, and how much worse it is plausibly getting.
Audit trail
Everything this entry has been through — when it was first searched for, queued, reviewed and approved, and how its figures and rank have moved since.
Loading history…